Hostname: page-component-74656f9884-rdgjk Total loading time: 0 Render date: 2026-11-08T15:03:01.310Z Has data issue: false hasContentIssue false

Understanding nano-bio interactions to improve nanocarriers for drug delivery

Published online by Cambridge University Press:  13 March 2014

Ryan M. Pearson
Affiliation:
University of Illinois at Chicago; rpears2@uic.edu
Hao-jui Hsu
Affiliation:
University of Illinois at Chicago; hhsu24@uic.edu
Jason Bugno
Affiliation:
University of Illinois at Chicago; jbugno2@uic.edu
Seungpyo Hong
Affiliation:
University of Illinois at Chicago; sphong@uic.edu

Abstract

The ability of cancer-targeted nanoparticles (NPs) to reach their site of action and evoke a desired biological response after intravenous injection is critical to achieve clinically significant in vivo efficacy. Throughout their journey in the body, NPs must successfully traverse biological environments such as blood circulation and tumor microenvironments. The interactions that occur at the interface between NPs and biological components are complex, requiring a thorough understanding of the “nano-bio” interactions to design NPs with maximal therapeutic indices. In this article, we review the challenges presented by the multiscale, important biocompartments that NPs face, describe the crucial nano-bio interactions present at each stage, and discuss potential strategies to overcome those challenges. This review suggests design considerations for NPs to optimally modulate their physicochemical properties to achieve desired biological responses, which are expected to aid chemists, engineers, and clinical scientists to design and develop highly effective delivery platforms for cancer therapy.

Information

Type
Research Article
Copyright
Copyright © Materials Research Society 2014 
Figure 0

Figure 1. Various barriers associated with nanoparticle (NP) delivery to tumor cells. To effectively achieve a therapeutic response, the NP must (a) survive blood circulation, (b) accumulate at the tumor site by extravasation through leaky tumor vasculature, (c) diffuse through the extracellular matrix to reach the target cell surface, (d) interact with the target cell surface, preferably via specific ligand-receptor interaction, and (e) internalize and bypass the degradation pathways associated with endocytosis to reach the subcellular target.

Figure 1

Figure 2. Characteristics of the tumor microenvironment. (a) Optical frequency-domain image of chaotic vasculature of the tumor environment. The color encodes depth: yellow (superficial) to red (deep) (scale bar: 500 μm). Reprinted with permission from Reference 149. © 2009 Macmillan Publishers Ltd. (b) Various interactions occurring within the tumor microenvironment: (1) diffusion and convection through the blood vessel; (2) interactions with fenestrations (perforations) and leaky endothelial connections; (3) high interstitial pressure, producing unfavorable mass transport away from the tumor; (4) fibroblasts and the secreted extracellular matrix (ECM) protein network; and (5) low core extracellular pH, increasing outward toward the periphery. (c) Scanning electron microscope image of a HN12 tumor ECM showing a dense collagen network (scale bar: 10 μm). Reproduced with permission from IOP Publishing. All rights reserved.51

Figure 2

Figure 3. Representative endocytosis mechanisms of nanoparticles. (a) Large particles are internalized by phagocytosis. (b) Internalization of smaller particles can occur through non-specific macropinocytosis (>1 μm). Other multiple internalization pathways are available to facilitate the uptake of nanoparticles such as (c) caveolar-mediated endocytosis (∼60 nm), (d) clathrin-mediated endocytosis (∼120 nm), and (e) clathrin-independent and caveolin-independent endocytosis (∼90 nm). Reprinted with permission from Reference 104. ©2010 Macmillan Publishers Ltd.

Figure 3

Figure 4. Desired intracellular trafficking of nanoparticles (NPs) through endosomal escape that enables NP accumulation in the cytosol and allows subcellular targeting. Appropriate design of NPs using materials can act as proton sponges or incorporation of fusiogenic peptides can alleviate NP degradation in the lysosome (shown as dotted NPs). After escaping the endosome, NPs accumulate in the cytosol and release their therapeutic cargo or navigate to more specific subcellular compartments such as the mitochondria or the nucleus to achieve more targeted effects.

Figure 4

Table I. Important features of nanoparticles (NPs) to enhance drug delivery.